NR · Niagen · TruNiagen
FDA-approved NAD+ precursor — the clinically studied alternative to NMN.
FDA
Approved
WADA
Not Listed
HALF-LIFE
~5–6 hours
ROUTE
Oral
SCHEDULE
Daily, morning
In Plain English
FDA-approved NAD+ precursor — the clinically studied alternative to NMN.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
ApprovedFDA approved for human use.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
OralAdministration via oral.
NAD+ restoration
Mitochondrial support
Neuroprotection
Muscle recovery
NR is an alternative NAD+ precursor that converts via a different enzymatic pathway than NMN. ChromaDex's branded form (Tru Niagen) was the first ingredient to receive FDA new dietary ingredient notification approval, making it the most regulatory-clean NAD+ precursor. Multiple human trials demonstrate reliable NAD+ elevation at 250–500 mg/day. It has a longer half-life than NMN but similar clinical outcomes.
Mild flushing at high doses (less than niacin)
Nausea occasionally
Headache initially
Generally very well tolerated
Choosing NR vs NMN based on brand marketing — human trial outcomes are comparable; cost, availability, and regulatory preference are the practical differentiators
Not verifying third-party testing — NR product quality varies; ChromaDex's branded TruNiagen has the most rigorous verification
Combining with niacin (vitamin B3) — niacin competitively inhibits NR's NAD+ conversion pathway; don't take together
Niacin (vitamin B3) — competitive inhibition of the NAD+ conversion pathway; avoid combining
Resveratrol and pterostilbene — same synergistic longevity combination as NMN; sirtuin activation is required to harness elevated NAD+
Alcohol — depletes NAD+ stores rapidly; reduces the benefit of supplementation
NR has the cleanest regulatory standing of any NAD+ precursor — FDA new dietary ingredient notification approved, unlike NMN which faced FDA reclassification attempts. If regulatory clarity matters, NR is the safer choice. Outcomes vs NMN are comparable in human studies. The core principle remains the same: always pair with a sirtuin activator.
Stats
Sources & Studies
Trammell SA. et al., Nat Commun, 2016